From: Nick Mulcahy From: medscape.com The US Food and Drug Administration (FDA) issued a warning today that the commonly prescribed breast cancer therapies known as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors may cause rare but severe inflammation of the lungs. The related products include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Eli Lilly), which are approved for use …
-
-
Regrets After a Cancer Diagnosis
-
You Are Not Alone After a Breast Cancer Diagnosis
-
The Past and Future Collide After a Breast Cancer Diagnosis
-
Focusing on the Positive After a Breast Cancer Diagnosis
-
My Message of Easter for the Breast Cancer Community
